168 related articles for article (PubMed ID: 28239466)
1. Nivolumab induced myxedema crisis.
Khan U; Rizvi H; Sano D; Chiu J; Hadid T
J Immunother Cancer; 2017; 5():13. PubMed ID: 28239466
[TBL] [Abstract][Full Text] [Related]
2. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab.
Matsumura K; Nagasawa K; Oshima Y; Kikuno S; Hayashi K; Nishimura A; Okubo M; Uruga H; Kishi K; Kobayashi T; Mori Y
J Diabetes Investig; 2018 Mar; 9(2):438-441. PubMed ID: 28418115
[TBL] [Abstract][Full Text] [Related]
3. NIVOLUMAB ASSOCIATED ENDOCRINE ABNORMALITIES: CHALLENGING CASES FROM A REFERENCE CLINIC.
Unal MC; Semiz GG; Ozdoğan O; Altay C; Yildirim EC; Semiz HS; Comlekci A; Akinci B
Acta Endocrinol (Buchar); 2022; 18(4):516-522. PubMed ID: 37152877
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma.
Lopez J; Yarlagadda N; Gheith Z; Mohan M; Sasapu A
Proc (Bayl Univ Med Cent); 2020 Jan; 33(1):59-61. PubMed ID: 32063772
[TBL] [Abstract][Full Text] [Related]
5. Initial low-dose oral levothyroxine in a child with Down syndrome, myxedema, and cardiogenic shock.
Janson A; Hällström C; Iversen M; Finder M; Elimam A; Nergårdh R
Clin Case Rep; 2019 Jul; 7(7):1291-1296. PubMed ID: 31360469
[TBL] [Abstract][Full Text] [Related]
6. [Immune-related adverse events by immune checkpoint inhibitors].
Kadono T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):83-89. PubMed ID: 28603205
[TBL] [Abstract][Full Text] [Related]
7. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab.
Kitajima K; Ashida K; Wada N; Suetsugu R; Takeichi Y; Sakamoto S; Uchi H; Matsushima T; Shiratsuchi M; Ohnaka K; Furue M; Nomura M
Jpn J Clin Oncol; 2017 May; 47(5):463-466. PubMed ID: 28334791
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
De Velasco G; Je Y; Bossé D; Awad MM; Ott PA; Moreira RB; Schutz F; Bellmunt J; Sonpavde GP; Hodi FS; Choueiri TK
Cancer Immunol Res; 2017 Apr; 5(4):312-318. PubMed ID: 28246107
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors in challenging populations.
Johnson DB; Sullivan RJ; Menzies AM
Cancer; 2017 Jun; 123(11):1904-1911. PubMed ID: 28241095
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.
Hida T; Nishio M; Nogami N; Ohe Y; Nokihara H; Sakai H; Satouchi M; Nakagawa K; Takenoyama M; Isobe H; Fujita S; Tanaka H; Minato K; Takahashi T; Maemondo M; Takeda K; Saka H; Goto K; Atagi S; Hirashima T; Sumiyoshi N; Tamura T
Cancer Sci; 2017 May; 108(5):1000-1006. PubMed ID: 28266091
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
Hickmott L; De La Peña H; Turner H; Ahmed F; Protheroe A; Grossman A; Gupta A
Target Oncol; 2017 Apr; 12(2):235-241. PubMed ID: 28255845
[TBL] [Abstract][Full Text] [Related]
13. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features.
Spain L; Schmid T; Gore M; Larkin J
Eur J Cancer; 2017 Apr; 75():243-244. PubMed ID: 28242501
[No Abstract] [Full Text] [Related]
15. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
[TBL] [Abstract][Full Text] [Related]
16. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
[TBL] [Abstract][Full Text] [Related]
17. Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?
Kong X; Kong Y
Onco Targets Ther; 2017; 10():1335-1344. PubMed ID: 28280368
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study.
Yamazaki N; Kiyohara Y; Uhara H; Uehara J; Fujimoto M; Takenouchi T; Otsuka M; Uchi H; Ihn H; Minami H
Cancer Sci; 2017 Jun; 108(6):1223-1230. PubMed ID: 28342215
[TBL] [Abstract][Full Text] [Related]
20. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Remon J; Besse B; Soria JC
BMC Med; 2017 Mar; 15(1):55. PubMed ID: 28285592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]